Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrimethamine in HPV-unrelated locally advanced HNSCC
NCT05678348Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pyrimethamine in head and neck squamous cell carcinoma (HNSCC), sponsored by Washington University School of Medicine. Primary endpoint: Change in Log2 of tumor DHFR expression at 14 days. Started Aug 2023; status: completed.
02
Drugs
pyrimethamine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05678348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05678348.